NEUROSOMIX
LIVE

Serial Number

79430633

Owner

LINKCARE HEALTH SERVICES, S.L.

Filing Date

Jun 17, 2025

Add to watchlist:

No watchlists yet
View on USPTO

NEUROSOMIX Trademark

Serial Number: 79430633

NEUROSOMIX is a trademark filed by LINKCARE HEALTH SERVICES, S.L. on June 17, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

LINKCARE HEALTH SERVICES, S.L. (3 trademarks)

ROGER DE LLURIA, 50, SOBREATICO A

Entity Type: 99

Trademark Details

Filing Date

June 17, 2025

Registration Date

Not Registered

Goods & Services

Chemical preparations for analyses in laboratories, except for medical or veterinary use; chemical reagents, except for medical or veterinary purposes; diagnostic preparations and reagents, except for medical or veterinary use; chemical diagnostic preparations for scientific purposes; diagnostic scanning agents for in vivo scientific use; diagnostic preparations for clinical diagnostic use, except for medical or veterinary use; diagnostic kits comprising sample receptors, synthetic antibody-like bioreceptors for the detection of biomarkers related oncology and reagents for analyzing selected bacteria, except for medical or veterinary use; diagnostic test materials, except for medical use, namely, diagnostic preparations for in vitro testing for scientific use; chemical preparations for use in immunoassay testing, except for medical or veterinary use; immunoassay reagents, except for medical or veterinary use.

Skin cleansing preparations for medical use; biological preparations for use in cell cultures for medical purposes; chemical preparations for medical use, namely, for the treatment and detection of cancer; chemico-pharmaceutical preparations for the treatment and detection of cancer; diagnostic preparations for medical use; chemical reagents for medical or veterinary use; diagnostic reagents for medical use; reagents for clinical diagnosis for medical use; reagents for clinical analysis for medical use; reagents with biomarkers for medical diagnostics; immunoassay reagents for medical use; diagnostic test materials for medical use, namely, diagnostic test reagents for medical use

Medical apparatus and instruments, namely, in vitro diagnostic devices for the detection, assessment, evolution and response to treatment of diseases based on the analysis of biomarkers in extracellular vesicles derived from neurons; diagnostic apparatus for medical use, namely, medical diagnostic apparatus for testing in vitro diagnostic devices for the detection, assessment, evolution, and tracking of the response to treatment of cancerous diseases based on analysis of biomarkers in extracellular vesicles derived from cancer; detector apparatus for medical use in diagnostics, namely, medical diagnostic apparatus for testing in vitro diagnostic devices for the detection, assessment, evolution, and tracking of the response to treatment of cancerous diseases based on analysis of biomarkers in extracellular vesicles derived from cancer; diagnostic testing apparatus for medical purposes for detecting cancer; medical equipment for diagnosis, examination, and monitoring in the form of respiratory equipment and monitors for the same; tools for medical diagnostics, namely, medical devices and surgical instruments for use in diagnosis and surgery of the gastrointestinal tract; medical diagnostic instruments for the analysis of bodily fluids; testing instruments for medical diagnostic use in the form of ultrasonic medical diagnostic apparatus; medical diagnostic instruments for use in immunoassay procedures, such as immunochemical medical diagnostic apparatus for detecting and measuring antibody levels; immunological analyzers such as immunochemical testing apparatus for medical use

Filing History

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 11, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 11, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 31, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 30, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 30, 2026 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 13, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 21, 2025 REPR